Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immune Killer Cell
- Development stage
- Phase 2
- Lead developer
- Ivy Life Sciences
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Immune Killer Cell (IKC) is a proprietary autologous immune cell therapy developed by Ivy Life Sciences. The therapy involves the extraction of a patient's own peripheral blood mononuclear cells (PBMCs), which are then activated and expanded ex vivo using a specific cytokine cocktail to generate a population of highly potent 'killer cells' (typically characterized as Cytokine-Induced Killer or CIK cells). These cells exhibit dual characteristics of T cells and Natural Killer (NK) cells, allowing them to recognize and eliminate a broad range of cancer cells in a non-MHC-restricted manner. Once re-infused into the patient, IKC targets malignant tissues while minimizing damage to healthy cells. The platform is primarily being investigated for the treatment of solid tumors, including glioblastoma multiforme (GBM), hepatocellular carcinoma, and non-small cell lung cancer.
- Brand names
- IKC
- Other names
- IKCImmune Killer Cell
02
Targets
HLA-B7NKG2DL (NKG2D ligand family)MICB (Major histocompatibility complex class i-related protein B)NECTIN1 (Poliovirus receptor-related 1)VCAM1 (Vascular cell adhesion molecule 1)
Beyond the preview
Go deeper on Immune Killer Cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune Killer Cell.